Battered by the second wave of covid-19, the government recalibrates its vaccination strategy in the hope of inoculating India's 900 million adult population by December 31. How realistic is this target? - Issue Date: Jun 21, 2021
Just as India s drug manufacturers and pharma businesses are catching up with demands for anti-viral drug Remdesivir, plans are afoot to remove the drug from the list.
COVID relief works on Rajiv’s anniversary
Telangana Pradesh Congress Committee president and Nalgonda MP N Uttam Kumar Reddy said Chief Minister K. Chandrashekhar Rao was not responding to the appeals to include COVID-19 treatment in Arogyasri while several other States were already providing free treatment to all the COVID patients.
Addressing the representatives of rural local bodies in a meeting being held by Panchayat Raj Sanghatan on virtual mode, he said TRS government’s attitude on the pandemic was inhuman. Despite lack of beds, injections and medicines shortage the government has not taken any concrete steps to mitigate the problems of people.
Remdesivir output up, but supply bottlenecks remain
×
The production of most sought after anti-viral drug, Remdesivir, has increased significantly but its availability continues to be a challenge in some States and private hospitals.
The production capacity of the remdesivir injection by seven domestic manufacturers has increased from 38 lakh vials per month to nearly 119 lakh vials, the Ministry of Chemicals and Fertilisers said on Monday.
Developed by US-based Gilead Sciences Inc, Remdesivir is being used to treat Covid-19 patients with oxygen saturation below 95 per cent and those with moderate to severe symptoms. Hyderabad-based Hetero Drugs is a major manufacturer of Remdisivir followed by Cipla, Zydus Cadila, Mylan Labs, Dr Reddy’s Labs, Syngene and Jubilant Ingrevia.